In recent years, prevention has become a major focus of Alzheimer disease (AD) research because once AD pathology has advanced, treating patients at this stage does little to slow disease progression or improve cognitive function.
The focus of our research at Cleveland Clinic and increasing numbers of other centers has therefore been identifying the brain changes that happen a decade or more before clinical symptoms manifest and finding biomarkers that can be used to assess interventions that can slow or prevent disease progression.